Trials / Completed
CompletedNCT01642004
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 272 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | |
| DRUG | Docetaxel |
Timeline
- Start date
- 2012-10-16
- Primary completion
- 2014-11-17
- Completion
- 2021-08-16
- First posted
- 2012-07-17
- Last updated
- 2022-12-28
- Results posted
- 2016-03-17
Locations
127 sites across 21 countries: United States, Argentina, Australia, Austria, Canada, Chile, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Netherlands, Norway, Peru, Poland, Romania, Russia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01642004. Inclusion in this directory is not an endorsement.